<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In an attempt to reestablish <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis in symptomatic <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and to show the tolerability of a combination treatment of low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (LD AraC) and interleukin-3 (IL-3), we treated 31 patients (pts., median age 65 years) who had more than 10% blasts in the bone marrow (BM) and hematopoietic failure with LD AraC (2 x 10 mg/m2 sc, day 1-14) plus IL-3 (once daily sc, day 8-21) at different dose steps (1.0, 2.5, 5.0, and 10.0 micrograms/kilogram body weight) </plain></SENT>
<SENT sid="1" pm="."><plain>The numbers of each 21-day cycle varied between 1 (3 pts.), 2 (6 pts.), 3 (8 pts.), 4 (1 pt.), 5 (5 pts.), and 6 (8 pts.), in total 116 cycles on an outpatient basis </plain></SENT>
<SENT sid="2" pm="."><plain>Subjective tolerability was good in 20 cases (65%) </plain></SENT>
<SENT sid="3" pm="."><plain>Toxicities were <z:hpo ids='HP_0001945'>fever</z:hpo> (29 pts.), flu-like symptoms (17 pts.), <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> (15 pts.), hepatic toxicity (10 pts.), and skin reactions (8 pts.) </plain></SENT>
<SENT sid="4" pm="."><plain>Overall response was seen in 13 cases (42%) and 5 complete responses (CR), while 10 pts. had stable disease (SD), 5 progressed (2 to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>), 2 were considered toxic <z:hpo ids='HP_0011420'>deaths</z:hpo>, and 1 died due to the disease </plain></SENT>
<SENT sid="5" pm="."><plain>Median survival is 18 months, progression-free survival is 12.5 months (18.0 months in responding pts.), with an actuarial follow-up of 31 months </plain></SENT>
<SENT sid="6" pm="."><plain>The data from this phase I/II study show that a combination of LD-AraC and IL-3 is well tolerated and that stable responses can be achieved in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> by means of an easy outpatient therapy </plain></SENT>
</text></document>